The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 15, 2025

Filed:

Aug. 08, 2019
Applicant:

Cellaster, Inc., Incheon, KR;

Inventors:

Kyung Chul Choi, Seoul, KR;

Ho Geun Yoon, Goyang-si, KR;

Jae Ho Cheong, Seoul, KR;

Mi Hyeon Jeong, Jeonju-si, KR;

Assignee:

Cellaster, Inc., Incheon, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 16/18 (2013.01); C12N 15/113 (2013.01); G01N 33/574 (2013.01);
Abstract

In the present disclosure, the effect of the TGFβ/Smad3/EPB41L5 molecular mechanism on cancer cells has been identified, and it has been found that high expression of EPB41L5 is correlated with poor overall survival of cancer patients, indicating that EPB41L5 is a potential prognostic marker of cancer. Thus, the present disclosure specifies an epitope of EPB41L5 to allow EPB41L5 to be recognized as an antigen, and relates to an antibody or a fragment thereof which binds specifically to the epitope. The antibody according to the present disclosure may be usefully employed as a therapeutic agent for EPB41L5-related cancer.


Find Patent Forward Citations

Loading…